d 13

D13 is an acylhydrazone antifungal.1 It is active against C. neoformans in vitro (MIC80 = 0.06 μg ml). D13 (20 mg kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection. |1. Lazzarini, C., Haranahalli, K., Rieger, R., et al. Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob. Agents Chemother. 62(5), e00156-00118 (2018).

The KD values of D13-9001 in Escherichia coli and Pseudomonas aeruginosa were 1.15μM and 3.57μM, respectively. D13-9001 has antibiotic activity. It is an effective AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor.

Choline-d13 Bromide (N,N,N-trimethyl-d9; 1,1,2,2-d4) 是 Choline Bromide 的氘代化合物。Choline Bromide 的 CAS 号为 1927-06-6。

Lusutrombopag-d13 是 Lusutrombopag 的氘代化合物。Lusutrombopag 的 CAS 号为 1110766-97-6。Lusutrombopag 是一种口服生物可利用的小分子血小板生成素 (TPO) 受体激动剂，用于选择性侵入性手术前患有血小板减少症的慢性肝病的患者。

Alachlo-d13 (2,6-diethylphenyl-d13) 是 Alachlo 的氘代化合物。

Colfosceril miristate-d13 (DMPC-d13) 是 Colfosceril miristate 的氘代物。Colfosceril miristate (DMPC) 是一种合成磷脂，适用于研究脂质体、脂质单层以及双层。

Mycophenolic acid-13C-d3 是 Mycophenolic acid 的 13C 和氘代化合物。Mycophenolic acid 的 CAS 号为 24280-93-1。Mycophenolic acid 是一种有效的非竞争性肌苷单磷酸脱氢酶 (IMPDH) 抑制剂，EC50为 0.24 µM。它对多种 RNA 病毒具有抗病毒作用。它也是一种免疫抑制剂，具有抗血管生成和抗肿瘤作用。

Homovanillic Acid-13C-d3 是 Homovanillic Acid 的 13C 和氘代化合物。Homovanillic Acid 的 CAS 号为 306-08-1。Homovanillic acid 是一种多巴胺代谢物，它与乳糜泻、生长激素缺乏、芳香族氨基酸脱羧酶缺乏症以及脂联素还原酶缺乏症相关。

Levomefolic Acid-13C-d3 是 Levomefolic Acid 的 13C 和氘代化合物。Levomefolic Acid 的 CAS 号为 31690-09-2。Levomefolic acid是一种具有口服活性、可穿过血脑屏障的天然活性叶酸，是广泛使用的叶酸食品补充剂。

β-Apo-13-carotenone D3 is the deuterium labeled β-Apo-13-carotenone. β-Apo-13-carotenone is an antagonist of RXRα.

13-cis Acitretin D3 (Isoacitretin D3) is a deuterium-labeled 13-cis Acitretin. 13-cis Acitretin is the metabolite of Acitretin after chronic administration. Acitretin is a second-generation, systemic retinoid.

11β,13-Dihydrotaraxinic acid β-D-glucopyranosyl ester 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN6271，CAS号为 75911-16-9。

13-cis Retinoyl β-D-glucuronide 是一种应用于糖生物学研究的生化试剂。糖生物学主要研究糖的结构、合成、生物学功能及其进化过程，涵盖了碳水化合物化学、聚糖的形成与降解酶学、蛋白质与聚糖的相互识别，以及聚糖在生物系统中的作用。该领域与基础研究、生物医学和生物技术紧密联系。

Apixaban 13C,d3是Apixaban的氘代标记物，可用于同位素示踪。 是一种选择性的凝血因子 Xa (Factor Xa) 抑制剂，用于研究血栓栓塞。

PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is a potent and selective HCV NS5B polymerase inhibitor.

D-Glucose-13C6 (Dextrose-13C6) 是一种 D-Glucose 的同位素标记物，可作为代谢示踪剂，可用于研究机体代谢相关疾病和部分物质的代谢过程。

Tiopronin 13C D3 is deuterium labeled Tiopronin.

D-(+)-Trehalose-13C12为D-(+)-Trehalose的13C同位素标记版，后者作为食品成分和赋形剂在广泛应用中。

D-Fructose-13C6 可用作通过 GC-或 LC-MS 定量 D-果糖的内标。

2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg ml.4,5In vivo, 2-deoxy-D-glucose (500 mg kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)

13C C16 Sphingomyelin is an isotopically enriched form of C16 sphingomyelin with carbon-13 occurring on the fatty acid portion. It is intended for use as an internal standard for the quantification of C16 sphingomyelin by GC- or LC-MS. C16 Sphingomyelin is a form of sphingomyelin containing palmitate (16:0) at the variable acylation position. It is the most common form of sphingomyelin found in eggs and is less abundant in the brain and in milk. C16 Sphingomyelin interacts with cholesterol in ordered lipid domains (lipid rafts). Sphingomyelinases remove phosphorylcholine from C16 sphingomyelin to produce C16 ceramide. While ceramides commonly induce apoptosis, ceramides with different fatty acid chain lengths might direct distinct functions and, in some cases, reduce apoptosis.

Prostaglandin D1 (PGD1) is the theoretical D-series metabolite of dihomo-γ-linolenic acid (DGLA), but to date it has not been isolated as a natural product. It is an inhibitor of ADP-induced platelet aggregation in humans with an IC50 value of 320 ng/ml, about 1/10 as potent as PGD2. 13,14-dihydro-15-keto Prostaglandin D1 (13,14-dihydro-15-keto PGD1) is the theoretical metabolite of PGD1 via the 15-hydroxy PG dehydrogenase metabolic pathway. No biological studies for this compound have been reported.

13C6 Glucosylsphingosine (d18:1) is an isotopically enriched form of 1-β-D-glucosylsphingosine (d18:1) that is intended for use as an internal standard for the quantification of 1-β-D-glucosylsphingosine by GC- or LC-MS. 1-β-D-Glucosylsphingosine is a lysolipid derivative of glucosylcerebroside that decreases activity of glucocerebrosidase in LA-N-2 cells in a dose-dependent manner.

KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.